Document is current
Any future updates will be listed below
-
Authors
Giordano, Giulia Maria https://orcid.org/0000-0002-5247-1117
Cattarinussi, Giulia
Lawrence, Andrew
Amasi-Hartoonian, Nare
Kretzer, Svenja
Ma, Xuemei
Pollard, Rebecca
Vallée, Corentin
Mucci, Armida
Galderisi, Silvana
Dazzan, Paola
-
Funding
Funding for this research was provided by:
Università degli Studi della Campania Luigi Vanvitelli
- License Information
-
More Information
Article History
Received: 11 June 2025
Accepted: 31 January 2026
First Online: 12 February 2026
Declarations
:
: GM G has been a consultant for Angelini. NA-H is the recipient of a Ph.D. studentship funded by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The authors acknowledge infrastructure funding from the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London (Grant No. NIHR203318). The views expressed are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. AM received advisory board/ consultant fees from the following drug companies: Angelini, Boehringer Ingelheim, Pierre Fabre and Rovi Pharma. SG received advisory board/consultant fees, or honoraria/expenses from the following drug companies: Angelini, Gedeon Richter-Recordati, Innova Pharma-Recordati Group, Janssen Cilag, Janssen Pharmaceutica NV, Lundbeck Italia, Rovi and Recordati Pharmaceuticals. PD has received speaker’s fees from Lundbeck and Janssen. However, this paper is independent from this funding; there are no further declarations of interest.
